Johnson & Johnson Announces the Release of EVARREST Patch

Morayma Reyes

Morayma Reyes

Johnson & Johnson released good news that their sealant patch, EVARREST, faced additional indication (one more approved reason for surgical application) by the FDA to give to patients suffering from atypical and prolonged hemorrhaging, a cheaper way to ward off negative results. EVARREST uses biogenics such as resilient proteins found naturally at the site of blood clotting, to create a kind of hemostatic patch that works to fuse with muscle tissue and close off openings. The patch is bioabsorbable and body-friendly, and requires manual compression to activate.

Blood loss, especially during surgical procedures, is a leading cause of complications that severely endanger a patient’s life. In a recent study, the hemostat was shown to be more than 94% successful than older and more expensive mechanisms across a wide range of surgical cases. This has proved itself to be a saving grace in certain high-risk settings, and will continue to offer both patients and doctors a little peace of mind, relaxing the typical tensions in an OR room.

EVARREST was initially approved in 2012 as an adjunct to hemostasis including abdominal, pelvic, and non-thoracic procedures, but now received further approbation for usage in cases of liver hemorrhage where suturing, cautery and ligature are insufficient. The liver is a hearty organ and is responsible for a great contribution to homeostasis. When it bleeds, it can be very difficult to control, let alone stop, and EVARREST offers the first reassurance of facility.

A few caveats mentioned for practitioners: the patch cannot be used intravascularly; it must be used topically to the exterior of an organ, and not near an infected area. The patch is a supplement to other hemostatic measures, not a sole and sufficient method. Patients with history of anaphylaxis should not receive the patch. Repeated use of the patch, especially covering the same area has not been adequately studied, and has been faced with adverse effects including but not limited to post-operational hemorrhage, anemia, deep vein thrombosis, and increased inflammation.